Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > Fc gamma RIIIA / CD16a > CDA-H5220

Human Fc gamma RIIIA / CD16a (F176) Protein, His Tag (MALS & SPR verified)

Order Now

  • Synonym
    FCGR3A,CD16A,FCG3,FCGR3,IGFR3
  • Source
    Human CD16a (F176), His Tag(CDA-H5220) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
    Predicted N-terminus: Gly 17
  • Molecular Characterization
    Fc gamma RIIIA / CD16a Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 23.7 kDa. The protein migrates as 39-51 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
Fc gamma RIIIA / CD16a SDS-PAGE

Human CD16a (F176), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
Fc gamma RIIIA / CD16a MALS images

The purity of Human CD16a (F176), His Tag (Cat. No. CDA-H5220) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.

Bioactivity-SPR
 Fc gamma RIIIA / CD16a SPR

Human CD16a (F176), His Tag (Cat. No. CDA-H5220) captured on CM5 chip via anti-His antibody can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 1.18 µM as determined in a SPR assay (Biacore 8K) (QC tested).

 Fc gamma RIIIA / CD16a SPR

Rituximab biosimilar (Cat. No. CD0-M36) captured on Protein A Chip can bind Human CD16a (F176), His Tag (Cat. No. CDA-H5220) with an affinity constant of 1.98 µM as determined in a SPR assay (Biacore 8K) (Routinely tested).

  • Background
    CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
    CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $220.00

Price(USD) : $280.00

Price(USD) : $1980.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:12 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message